Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Caplin Point Lab
-
Master Rating:
-
Caplin Point Labs. has an operating revenue of Rs. 1,157.07 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 30% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 12% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 26% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 93 which is a GREAT score indicating consistency in earnings, a RS Rating of 61 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Caplin Point Laboratories Ltd Forecast
Price Estimates
Eps And Sales Estimates
Caplin Point Laboratories Ltd Synopsis
NSE-Medical-Generic Drugs
Caplin Point Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 482.68 Cr. and Equity Capital is Rs. 15.13 Cr. for the Year ended 31/03/2021. Caplin Point Laboratories Ltd. is a Public Limited Listed company incorporated on 16/04/1990 and has its registered office in the State of Tamil Nadu, India. Company’s Corporate Identification Number(CIN) is L24231TN1990PLC019053 and registration number is 019053.-
Market Cap
INR 6,080.46 Cr
-
Sales
INR 533.94 Cr
-
Shares in Float
2.35 Cr
-
No of Funds
52 K
-
Yield
0.37%
-
Book Value
8
-
U/D Vol Ratio
1.4
-
LTDebt/Equity
%
-
Alpha
0.14
-
Beta
0.78
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 69.03% | 69.03% | 69.03% |
| Mutual Funds | 0.99% | 0.45% | 0.38% |
| Insurance Companies | 0.34% | 0.33% | 0.22% |
| Foreign Portfolio Investors | 1.15% | 0.68% | 1.64% |
| Financial Institutions/ Banks | 0.11% | 0.5% | 0.5% |
| Individual Investors | 21.69% | 22.95% | 22.4% |
| Others | 6.69% | 6.06% | 5.83% |
| Name | Designation |
|---|---|
| Mr. C C Paarthipan | Chairman |
| Dr. Sridhar Ganesan | Managing Director |
| Mr. V Thirumalai | Independent Director |
| Mr. R Viswanathan | Independent Director |
| Dr. K C John | Independent Director |
| Mr. D Sathyanarayanan | Independent Director |
| Dr. C K Gariyali | Independent Director |
| Mr. D P Mishra | Director |
Caplin Point Laboratories Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 160.4 | 127.5 | 122.88 | 123.16 | 116.92 |
| Operating Expenses Qtr Cr | 89 | 71.19 | 79.6 | 66.18 | 60.7 |
| Operating Profit Qtr Cr | 71.4 | 56.31 | 43.28 | 56.98 | 56.22 |
| Depreciation Qtr Cr | 6.31 | 6.2 | 5.97 | 5.61 | 5.43 |
| Interest Qtr Cr | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 |
| Tax Qtr Cr | 18.33 | 14.86 | 13.15 | 13.83 | 12.73 |
| Net Profit Qtr Cr | 65.16 | 54.55 | 31.49 | 41.48 | 41.26 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 501.2976 | 593.7966 | 572.307 | 449.8872 | 354.0618 |
| Operating Expenses Annual Cr | 268.7548 | 320.8329 | 348.7502 | 284.7852 | 248.0961 |
| Operating Profit Annual in Cr | 213.9248 | 206.9924 | 188.1555 | 141.7887 | 93.4532 |
| Depreciation Cr | 22.4408 | 19.6538 | 20.8432 | 18.9878 | 13.2599 |
| Interest Annual Cr | 0.1667 | 0.185 | 0.0598 | 0.0612 | 0.1275 |
| Tax Annual Cr | 53.7155 | 55.4864 | 54.4873 | 43.7421 | 22.2613 |
| Net Profit Annual Cr | 156.2198 | 197.6385 | 148.1665 | 102.3109 | 70.317 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 294.6452 | 87.0055 | 107.3447 | 22.6066 | 55.49 |
| Cash from Investing Activity Annual Cr | 16.28 | -41.0559 | -76.5138 | -59.7113 | -37.0724 |
| Cash from Financing Annual Activity Cr | -3.4634 | -32.9184 | -15.2101 | -11.5994 | -6.743 |
| Net Cash Flow Annual Cr | 307.4618 | 13.0312 | 15.6208 | -48.7041 | 11.6746 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 758.6734 | 599.9054 | 432.045 | 295.6043 | 200.1161 |
| Fixed Assets Annual Cr | 184.048 | 170.6982 | 146.3861 | 184.6102 | 155.1658 |
| Total Non Current Assets Annual Cr | 328.3547 | 310.591 | 251.374 | 197.5929 | 180.337 |
| Total Current Assets Annual Cr | 532.6478 | 380.7363 | 287.9513 | 213.2094 | 136.7281 |
| Total Assets Annual Cr | 861.0025 | 691.3273 | 539.3253 | 410.8023 | 317.0651 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 100.2964 | 79.3074 | 57.1256 | 39.0992 | 26.4786 |
| ROE Annual % | 20.59 | 32.94 | 34.29 | 34.61 | 35.13 |
| ROCE Annual % | 26.81 | 40.39 | 44.37 | 45.17 | 42.13 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 48.17 | 51.71 | 41.63 | 38.7 | 31.02 |
Caplin Point Laboratories Ltd Technicals
EMA & SMA
CURRENT PRICE
802.5 
(4.87)
-
- Bullish Moving Averages 9
- Bearish Moving Averages 7
EMA
-
20 Day
807.39
-
50 Day
827.86
-
100 Day
795.88
-
200 Day
683.47
Caplin Point Laboratories Ltd Resistance and support
757.74 PIVOT
-
First Resistance
787.47
-
Second Resistance
809.74
-
Third Resistance
839.47
-
First Support
735.47
-
Second Support
705.74
-
Third Support
683.47
-
RSI
46.44
-
MFI
60.98
-
MACD
-24.91
-
MACD signal line
-20.43
Caplin Point Laboratories Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 569,501 | 7,967,319 | 13.99% |
| Week | 369,081 | 11,972,975 | 32.44% |
| 1 Month | 203,455 | 7,275,560 | 35.76% |
| 6 Month | 572,246 | 13,499,281 | 23.59% |
Caplin Point Laboratories Ltd Price change analysis
-26.55
Over 1 month
Low High 722.25 890
64
Over 3 month
Low High 722.25 1008.4
212.15
Over 6 months
Low High 585 1034.8
321.05
Over Year
Low High 401 1034.8Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | 850.00 | 768.55 (3.11%) | 520895 |
| Lupin Ltd | 1,267.50 | 875.70 (0.51%) | 60693 |
| Aurobindo Pharma Ltd | 1,063.75 | 673.35 (1.66%) | 32187 |
| Lasa Supergenerics Ltd | 100.15 | 64.00 (6.05%) | 33627 |
News
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 3
Loss of Share Certificate of Mr. Ganesan R Read More
Buy Caplin Point Laboratories; target of Rs 1080: ICICI Dire
ICICI Direct is bullish on Caplin Point Laboratories has recommended buy rating on the stock with a target price of Rs 1080 in its research Read More
Caplin Labs Standalone September 2021 Net Sales at Rs 160.40
NULL Read More
Caplin Point Laboratories Ltd - 524742 - Announcement under
Allotment of Equity Shares on Exercise of ESOPs Read More
Earnings Call for Q2FY22 of Caplin Point Laboratories
Conference Call with Caplin Point Laboratories Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transc Read MoreBlogs